.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Healthtrust
Mallinckrodt
Daiichi Sankyo
Deloitte
QuintilesIMS
Federal Trade Commission
Citi
UBS

Generated: February 19, 2018

DrugPatentWatch Database Preview

US Patents With Foreign Priority to Germany Patent: 101 14 178

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi Aventis UsAPIDRAinsulin glulisine recombinantINJECTABLE;IV (INFUSION), SUBCUTANEOUS021629-001Apr 16, 2004RXYesYes➤ Sign Up➤ Sign UpYMETHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
Sanofi Aventis UsAPIDRAinsulin glulisine recombinantINJECTABLE;IV (INFUSION), SUBCUTANEOUS021629-002Dec 20, 2005RXYesYes➤ Sign Up➤ Sign UpYMETHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
Sanofi Aventis UsAPIDRA SOLOSTARinsulin glulisine recombinantINJECTABLE;SUBCUTANEOUS021629-003Feb 24, 2009RXYesNo➤ Sign Up➤ Sign UpYMETHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
Sanofi Aventis UsAPIDRAinsulin glulisine recombinantINJECTABLE;IV (INFUSION), SUBCUTANEOUS021629-001Apr 16, 2004RXYesYes➤ Sign Up➤ Sign UpY
Sanofi Aventis UsAPIDRAinsulin glulisine recombinantINJECTABLE;IV (INFUSION), SUBCUTANEOUS021629-002Dec 20, 2005RXYesYes➤ Sign Up➤ Sign UpY
Sanofi Aventis UsAPIDRA SOLOSTARinsulin glulisine recombinantINJECTABLE;SUBCUTANEOUS021629-003Feb 24, 2009RXYesNo➤ Sign Up➤ Sign UpY
Sanofi Aventis UsAPIDRAinsulin glulisine recombinantINJECTABLE;IV (INFUSION), SUBCUTANEOUS021629-001Apr 16, 2004RXYesYes➤ Sign Up➤ Sign UpYMETHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
Sanofi Aventis UsAPIDRAinsulin glulisine recombinantINJECTABLE;IV (INFUSION), SUBCUTANEOUS021629-002Dec 20, 2005RXYesYes➤ Sign Up➤ Sign UpYMETHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
Sanofi Aventis UsAPIDRA SOLOSTARinsulin glulisine recombinantINJECTABLE;SUBCUTANEOUS021629-003Feb 24, 2009RXYesNo➤ Sign Up➤ Sign UpYMETHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist